Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer

Helga Weber, José R. Valbuena, Mustafa A. Barbhuiya, Stefan Stein, Hana Kunkel, Patricia García, Carolina Bizama, Ismael Riquelme, Jaime A. Espinoza, Stephen E. Kurtz, Jeffrey Tyner, Juan Francisco Calderon, Alejandro H. Corvalán, Manuel Grez, Akhilesh Pandey, Pamela Leal-Rojas, Juan C. Roa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NODSCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors. In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies. In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05). The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%). Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.

Original languageEnglish (US)
Pages (from-to)26169-26184
Number of pages16
JournalOncotarget
Volume8
Issue number16
DOIs
StatePublished - 2017

Fingerprint

tanespimycin
Gallbladder Neoplasms
Neoplasms
Therapeutics
G2 Phase Cell Cycle Checkpoints
Cyclin B1
Cyclin D1
Cell Movement
Cell Survival
Radiotherapy
Survival Rate
Immunohistochemistry
Apoptosis
Staining and Labeling
Drug Therapy
Cell Line

Keywords

  • 17-AAG
  • Gallbladder cancer
  • Gallbladder cancer xenografts
  • Geldanamycin
  • HSP90 inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Weber, H., Valbuena, J. R., Barbhuiya, M. A., Stein, S., Kunkel, H., García, P., ... Roa, J. C. (2017). Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. Oncotarget, 8(16), 26169-26184. https://doi.org/10.18632/oncotarget.15410

Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. / Weber, Helga; Valbuena, José R.; Barbhuiya, Mustafa A.; Stein, Stefan; Kunkel, Hana; García, Patricia; Bizama, Carolina; Riquelme, Ismael; Espinoza, Jaime A.; Kurtz, Stephen E.; Tyner, Jeffrey; Calderon, Juan Francisco; Corvalán, Alejandro H.; Grez, Manuel; Pandey, Akhilesh; Leal-Rojas, Pamela; Roa, Juan C.

In: Oncotarget, Vol. 8, No. 16, 2017, p. 26169-26184.

Research output: Contribution to journalArticle

Weber, H, Valbuena, JR, Barbhuiya, MA, Stein, S, Kunkel, H, García, P, Bizama, C, Riquelme, I, Espinoza, JA, Kurtz, SE, Tyner, J, Calderon, JF, Corvalán, AH, Grez, M, Pandey, A, Leal-Rojas, P & Roa, JC 2017, 'Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer', Oncotarget, vol. 8, no. 16, pp. 26169-26184. https://doi.org/10.18632/oncotarget.15410
Weber, Helga ; Valbuena, José R. ; Barbhuiya, Mustafa A. ; Stein, Stefan ; Kunkel, Hana ; García, Patricia ; Bizama, Carolina ; Riquelme, Ismael ; Espinoza, Jaime A. ; Kurtz, Stephen E. ; Tyner, Jeffrey ; Calderon, Juan Francisco ; Corvalán, Alejandro H. ; Grez, Manuel ; Pandey, Akhilesh ; Leal-Rojas, Pamela ; Roa, Juan C. / Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. In: Oncotarget. 2017 ; Vol. 8, No. 16. pp. 26169-26184.
@article{d2732ba08e4b4def80464b3550edef23,
title = "Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer",
abstract = "Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NODSCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors. In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies. In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6{\%} reduction in tumor size in the treatment group compared to control mice (p < 0.05). The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87{\%}) and it was strongly expressed in 70 cases (33{\%}), moderately in 58 cases (28{\%}), and weakly in 54 cases (26{\%}). Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.",
keywords = "17-AAG, Gallbladder cancer, Gallbladder cancer xenografts, Geldanamycin, HSP90 inhibitors",
author = "Helga Weber and Valbuena, {Jos{\'e} R.} and Barbhuiya, {Mustafa A.} and Stefan Stein and Hana Kunkel and Patricia Garc{\'i}a and Carolina Bizama and Ismael Riquelme and Espinoza, {Jaime A.} and Kurtz, {Stephen E.} and Jeffrey Tyner and Calderon, {Juan Francisco} and Corval{\'a}n, {Alejandro H.} and Manuel Grez and Akhilesh Pandey and Pamela Leal-Rojas and Roa, {Juan C.}",
year = "2017",
doi = "10.18632/oncotarget.15410",
language = "English (US)",
volume = "8",
pages = "26169--26184",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer

AU - Weber, Helga

AU - Valbuena, José R.

AU - Barbhuiya, Mustafa A.

AU - Stein, Stefan

AU - Kunkel, Hana

AU - García, Patricia

AU - Bizama, Carolina

AU - Riquelme, Ismael

AU - Espinoza, Jaime A.

AU - Kurtz, Stephen E.

AU - Tyner, Jeffrey

AU - Calderon, Juan Francisco

AU - Corvalán, Alejandro H.

AU - Grez, Manuel

AU - Pandey, Akhilesh

AU - Leal-Rojas, Pamela

AU - Roa, Juan C.

PY - 2017

Y1 - 2017

N2 - Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NODSCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors. In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies. In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05). The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%). Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.

AB - Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NODSCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors. In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies. In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05). The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%). Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.

KW - 17-AAG

KW - Gallbladder cancer

KW - Gallbladder cancer xenografts

KW - Geldanamycin

KW - HSP90 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85017516858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017516858&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15410

DO - 10.18632/oncotarget.15410

M3 - Article

AN - SCOPUS:85017516858

VL - 8

SP - 26169

EP - 26184

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -